EXELIXIS, INC. (EXEL)
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Address
1851 HARBOR BAY PARKWAY
ALAMEDA, CA 94502
Founded
1994
Number of Employees
1,310
Website
http://www.exelixis.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | - | - | - | $550 | $450 | $500 |
| Average Price | - | - | - | - | - | - | - | - | - | $20.97 | $22.17 | $21.49 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | 26,230 | 20,300 | 23,265 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | 24.0% | 17.3% | 21.0% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | 31.3% | 7.4% | 19.4% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | -7.3% | 9.9% | 1.6% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | 65% | 74% | 56% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at EXEL make a trade.
Creating a free account takes less than one minute